Form 4: MAIA Biotechnology Director Ramiro Guerrero Acquires Shares and Warrants

Director Ramiro Guerrero purchased 20,000 shares of MAIA Biotechnology and related warrants on May 8, 2025, at a price of $1.50 per share and $2.05 per warrant.

Summary

• On May 8, 2025, Ramiro Guerrero, a director of MAIA Biotechnology, Inc., acquired 20,000 shares of common stock at $1.50 per share.
• The purchase was made under the Issuer's 2021 Equity Incentive Plan.
• Guerrero also acquired 20,000 warrants at $2.05 each, which are deemed options under the same plan.
• The options are exercisable starting May 8, 2026, and expire on May 8, 2031.
• Following the transaction, Guerrero directly owns 588,218 shares of MAIA Biotechnology.
• The warrants are exercisable for common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the director's purchase of shares and warrants, indicating confidence in the company. However, it's not overwhelmingly positive as the purchase size is relatively modest.

Positives

• A director's purchase of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements, but the director's investment suggests a positive outlook.

Industry Context

Director share purchases are common in the biotechnology industry and are often viewed as a sign of confidence in the company's prospects. This is especially relevant for companies like MAIA Biotechnology, where clinical trial outcomes and regulatory approvals can significantly impact stock value.

Comparison to Industry Standards

• Comparing this transaction to similar insider purchases in comparable biotech firms, the size of the purchase (20,000 shares) is relatively modest.
• For instance, directors at companies like Amgen or Gilead Sciences often purchase larger blocks of shares.
• However, for a smaller company like MAIA Biotechnology, a purchase of this size by a director can still be a significant signal to the market.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive signal.
• Employees may feel more secure knowing that a director is investing in the company.

Key Dates

Keywords

MAIA Biotechnology, Ramiro Guerrero, Director, Share Purchase, Warrants, Equity Incentive Plan, Beneficial Ownership